On a day when the Dow Jones Industrial Average
But instead, let's focus on what went right. We have a duo of biotechs that had a great showing, along with a medical-device maker popping after hours.
Investors in little-known ARCA Biopharma are 43% richer than they were when they woke up, all thanks to a positive trial result. The company's drug candidate, GencaroTM, is hoping to carve out space in the large and lucrative atrial fibrillation market. It had a 74% reduction in new a-fib onsets for patients with a relatively common genotype.
Don't feel bad if you've never heard of ARCA. Even after its rocket shot, the company's market cap is below $20 million. Considering a-fib treatments are where heavyweights like Bristol-Myers Squibb
Meanwhile, BioSante Pharmaceuticals
Finaly, Zoll Medical
For a handy way to keep track of the companies mentioned here, add them to our free My Watchlist feature:
David Williamson owns shares of Johnson & Johnson, but he holds no other position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
5 Biotech Buyout Candidates for 2018
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
3 Stocks to Hold for the Next 20 Years
If you're looking for long-term stocks to buy, check out this trio that look primed for outperformance.
Why the Dogs of the Dow Look Doomed for 2017
The stocks that this popular strategy chose will produce gains, but they probably won't be big enough to beat the Dow overall.